U.S. Biotest, Inc.
Records under this name other than patents U.S. Biotest, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to U.S. Biotest, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,398,646 | Methods for Treating Lung Disorders now held by Crititech, Inc. In force · High confidence | In force | High confidence | |
| US 10,507,181 | Methods for Treating Lung Disorders now held by Crititech, Inc. In force · High confidence | In force | High confidence | |
| 16/239,530 | Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer now held by Crititech, Inc. Abandoned Abandoned Jun 17, 2020 | Abandoned | Abandoned Jun 17, 2020 | |
| 16/239,531 | Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles now held by Crititech, Inc. Abandoned Abandoned Jun 1, 2020 | Abandoned | Abandoned Jun 1, 2020 | |
| 16/382,446 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles now held by Crititech, Inc. Abandoned Abandoned Jun 11, 2021 | Abandoned | Abandoned Jun 11, 2021 | |
| 16/383,023 | Methods for Isolating Tumor-Specific Immune Cells from a Subject for Adoptive Cell Therapy and Cancer Vaccines now held by Crititech, Inc. Abandoned Abandoned Sep 28, 2020 | Abandoned | Abandoned Sep 28, 2020 | |
| 17/381,705 | Sorafenib particles and uses thereof now held by Crititech, Inc. Abandoned Abandoned Jul 28, 2023 | Abandoned | Abandoned Jul 28, 2023 | |
| 17/381,786 | Lapatinib particles and uses thereof now held by Crititech, Inc. Abandoned Abandoned Jul 27, 2022 | Abandoned | Abandoned Jul 27, 2022 |